Next Article in Journal
The Novel miRNA N-72 Regulates EGF-Induced Migration of Human Amnion Mesenchymal Stem Cells by Targeting MMP2
Next Article in Special Issue
Polarised VEGFA Signalling at Vascular Blood–Neural Barriers
Previous Article in Journal
Antimalarial Activity of Orally Administered Curcumin Incorporated in Eudragit®-Containing Liposomes
Previous Article in Special Issue
Oxygen-Induced Retinopathy from Recurrent Intermittent Hypoxia Is Not Dependent on Resolution with Room Air or Oxygen, in Neonatal Rats
Open AccessReview

The Janus Face of VEGF in Stroke

1
Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, 0371 Oslo, Norway
2
Institute for Behavioral Sciences, Faculty of Health Sciences, OsloMet—Oslo Metropolitan University, 0166 Oslo, Norway
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(5), 1362; https://doi.org/10.3390/ijms19051362
Received: 28 March 2018 / Revised: 27 April 2018 / Accepted: 1 May 2018 / Published: 4 May 2018
(This article belongs to the Special Issue Vascular Endothelial Growth Factor)
  |  
PDF [1083 KB, uploaded 24 May 2018]
  |  

Abstract

The family of vascular endothelial growth factors (VEGFs) are known for their regulation of vascularization. In the brain, VEGFs are important regulators of angiogenesis, neuroprotection and neurogenesis. Dysregulation of VEGFs is involved in a large number of neurodegenerative diseases and acute neurological insults, including stroke. Stroke is the main cause of acquired disabilities, and normally results from an occlusion of a cerebral artery or a hemorrhage, both leading to focal ischemia. Neurons in the ischemic core rapidly undergo necrosis. Cells in the penumbra are exposed to ischemia, but may be rescued if adequate perfusion is restored in time. The neuroprotective and angiogenic effects of VEGFs would theoretically make VEGFs ideal candidates for drug therapy in stroke. However, contradictory to what one might expect, endogenously upregulated levels of VEGF as well as the administration of exogenous VEGF is detrimental in acute stroke. This is probably due to VEGF-mediated blood–brain-barrier breakdown and vascular leakage, leading to edema and increased intracranial pressure as well as neuroinflammation. The key to understanding this Janus face of VEGF function in stroke may lie in the timing; the harmful effect of VEGFs on vessel integrity is transient, as both VEGF preconditioning and increased VEGF after the acute phase has a neuroprotective effect. The present review discusses the multifaceted action of VEGFs in stroke prevention and therapy. View Full-Text
Keywords: growth factor; VEGF; stroke; ischemia; exercise growth factor; VEGF; stroke; ischemia; exercise
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Geiseler, S.J.; Morland, C. The Janus Face of VEGF in Stroke. Int. J. Mol. Sci. 2018, 19, 1362.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top